Research Article
miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma
Table 2
miR-149-3p expression correlated with clinical and pathological features (logistic regression analysis).
| | Characteristics | Total (N) | Odds ratio (OR) | value |
| | Clinical stage (stage III and stage IV versus stage I and stage II) | 546 | 1.334 (0.919–1.940) | 0.130 | | Primary therapy outcome (CR versus PD, SD, and PR) | 475 | 0.501 (0.247–0.983) | 0.048 | | Race (White versus Asian and Black or African American) | 501 | 0.965 (0.646–1.441) | 0.861 | | Age (>60 versus ≤60) | 543 | 2.006 (1.411–2.863) | <0.001 | | Weight (>80 versus ≤80) | 523 | 0.756 (0.535–1.067) | 0.112 | | Height (>160 versus ≤160) | 519 | 1.109 (0.786–1.567) | 0.555 | | BMI (>30 versus ≤30) | 515 | 0.928 (0.652–1.319) | 0.676 | | Histological type (endometrioid versus mixed and serous) | 546 | 0.311 (0.204–0.470) | <0.001 | | Residual tumor (R0 versus R1 and R2) | 408 | 1.097 (0.557–2.182) | 0.789 | | Histologic grade ( versus and ) | 535 | 0.302 (0.183–0.485) | <0.001 | | Tumor invasion (%) (≥50 versus <50) | 470 | 1.608 (1.116–2.324) | 0.011 | | Menopause status (pre versus peri and post) | 500 | 0.603 (0.288–1.219) | 0.166 | | Hormones therapy (yes versus no) | 343 | 1.137 (0.609–2.123) | 0.686 | | Diabetes (yes versus no) | 445 | 1.191 (0.785–1.810) | 0.412 | | Radiation therapy (yes versus no) | 521 | 1.595 (1.129–2.259) | 0.008 | | Surgical approach (open versus minimally invasive) | 523 | 1.281 (0.902–1.822) | 0.168 |
|
|
